Technical Analysis for NERV - Minerva Neurosciences, Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Historical NERV trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Upper Bollinger Band Walk | Strength | 1.52% | |
| Wide Bands | Range Expansion | 1.52% | |
| Above Upper BB | Strength | 1.52% | |
| Overbought Stochastic | Strength | 1.52% | |
| Upper Bollinger Band Touch | Strength | 1.52% | |
| Crossed Above 50 DMA | Bullish | -2.90% | |
| MACD Bullish Centerline Cross | Bullish | -2.90% | |
| Pocket Pivot | Bullish Swing Setup | -2.90% | |
| Volume Surge | Other | -2.90% | |
| Wide Range Bar | Range Expansion | -2.90% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Get a Trading Assistant
- Earnings date: 11/02/2020
Minerva Neurosciences, Inc Description
Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Neuroscience Schizophrenia Parkinson's Disease Psychoactive Drugs Depressive Disorder Major Depressive Disorder Neurochemistry Treatment Of Parkinson's Disease Ketones Central Nervous System Disease Central Nervous System Diseases Treatment Of Major Depressive Disorder Antidepressants Insomnia Janssen Pharmaceutica Treatment Of Central Nervous System Diseases Cyren Dopamine Investigational New Drug
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.215 |
| 52 Week Low | 1.81 |
| Average Volume | 935,928 |
| 200-Day Moving Average | 4.48 |
| 50-Day Moving Average | 2.96 |
| 20-Day Moving Average | 2.60 |
| 10-Day Moving Average | 2.76 |
| Average True Range | 0.20 |
| ADX | 33.49 |
| +DI | 43.23 |
| -DI | 14.70 |
| Chandelier Exit (Long, 3 ATRs ) | 3.14 |
| Chandelier Exit (Short, 3 ATRs ) | 2.85 |
| Upper Bollinger Band | 3.17 |
| Lower Bollinger Band | 2.03 |
| Percent B (%b) | 1.11 |
| BandWidth | 44.05 |
| MACD Line | 0.06 |
| MACD Signal Line | -0.06 |
| MACD Histogram | 0.1226 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.77 | ||||
| Resistance 3 (R3) | 3.76 | 3.59 | 3.69 | ||
| Resistance 2 (R2) | 3.59 | 3.47 | 3.60 | 3.66 | |
| Resistance 1 (R1) | 3.45 | 3.40 | 3.37 | 3.46 | 3.64 |
| Pivot Point | 3.28 | 3.28 | 3.24 | 3.29 | 3.28 |
| Support 1 (S1) | 3.14 | 3.16 | 3.06 | 3.15 | 2.96 |
| Support 2 (S2) | 2.97 | 3.09 | 2.98 | 2.94 | |
| Support 3 (S3) | 2.83 | 2.97 | 2.91 | ||
| Support 4 (S4) | 2.84 |
